Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment

A follow-up study of the TORDIA sample

Benedetto Vitiello, Graham Emslie, Gregory Clarke, Karen Wagner, Joan R. Asarnow, Martin B. Keller, Boris Birmaher, Neal D. Ryan, Betsy Kennard, Taryn L. Mayes, Lynn DeBar, Frances Lynch, John Dickerson, Michael Strober, Robert Suddath, James T. McCracken, Anthony Spirito, Matthew Onorato, Jamie Zelazny, Giovanna Porta & 2 others Satish Iyengar, David A. Brent

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: We examined the long-term outcome of participants in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study, a randomized trial of 334 adolescents (aged 12-18 years) with DSM-IV-defined major depressive disorder initially resistant to selective serotonin reuptake inhibitor (SSRI) treatment who were subsequently treated for 12 weeks with another SSRI, venlafaxine, another SSRI + cognitive-behavioral therapy (CBT), or venlafaxine + CBT. Responders then continued with the same treatment through week 24, while nonresponders were given open treatment. Method: For the current study, patients were reassessed 48 (n = 116) and 72 (n = 130) weeks from intake. Data were gathered from February 2001 to February 2007. Standardized diagnostic interviews and measures of depression, suicidal ideation, related psychopathology, and level of functioning were periodically administered. Remission was defined as ≥ 3 weeks with ≤ 1 clinically significant symptom and no associated functional impairment (score of 1 on the adolescent version of the Longitudinal Interval Follow-Up Evaluation [A-LIFE]), and relapse, as ≥ 2 weeks with probable or definite depressive disorder (score of 3 or 4 on the A-LIFE). Mixed-effects regression models were applied to estimate remission, relapse, and functional recovery. Results: By 72 weeks, an estimated 61.1% of the randomized youths had reached remission. Randomly assigned treatment (first 12 weeks) did not influence remission rate or time to remission, but the group assigned to SSRIs had a more rapid decline in self-reported depressive symptoms and suicidal ideation than those assigned to venlafaxine (P < .03). Participants with more severe depression, greater dysfunction, and alcohol or drug use at baseline were less likely to remit. The depressive symptom trajectory of the remitters diverged from that of nonremitters by the first 6 weeks of treatment (P < .001). Of the 130 participants in remission at week 24, 25.4% relapsed in the subsequent year. Conclusions: While most adolescents achieved remission, more than one-third did not, and one-fourth of remitted patients experienced a relapse. More effective interventions are needed for patients who do not show robust improvement early in treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00018902.

Original languageEnglish (US)
Pages (from-to)388-396
Number of pages9
JournalJournal of Clinical Psychiatry
Volume72
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Treatment-Resistant Depressive Disorder
Serotonin Uptake Inhibitors
Depression
Suicidal Ideation
Cognitive Therapy
Recurrence
Therapeutics
Major Depressive Disorder
Depressive Disorder
Psychopathology
Diagnostic and Statistical Manual of Mental Disorders
Alcohols
Interviews

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment : A follow-up study of the TORDIA sample. / Vitiello, Benedetto; Emslie, Graham; Clarke, Gregory; Wagner, Karen; Asarnow, Joan R.; Keller, Martin B.; Birmaher, Boris; Ryan, Neal D.; Kennard, Betsy; Mayes, Taryn L.; DeBar, Lynn; Lynch, Frances; Dickerson, John; Strober, Michael; Suddath, Robert; McCracken, James T.; Spirito, Anthony; Onorato, Matthew; Zelazny, Jamie; Porta, Giovanna; Iyengar, Satish; Brent, David A.

In: Journal of Clinical Psychiatry, Vol. 72, No. 3, 03.2011, p. 388-396.

Research output: Contribution to journalArticle

Vitiello, B, Emslie, G, Clarke, G, Wagner, K, Asarnow, JR, Keller, MB, Birmaher, B, Ryan, ND, Kennard, B, Mayes, TL, DeBar, L, Lynch, F, Dickerson, J, Strober, M, Suddath, R, McCracken, JT, Spirito, A, Onorato, M, Zelazny, J, Porta, G, Iyengar, S & Brent, DA 2011, 'Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: A follow-up study of the TORDIA sample', Journal of Clinical Psychiatry, vol. 72, no. 3, pp. 388-396. https://doi.org/10.4088/JCP.09m05885blu
Vitiello, Benedetto ; Emslie, Graham ; Clarke, Gregory ; Wagner, Karen ; Asarnow, Joan R. ; Keller, Martin B. ; Birmaher, Boris ; Ryan, Neal D. ; Kennard, Betsy ; Mayes, Taryn L. ; DeBar, Lynn ; Lynch, Frances ; Dickerson, John ; Strober, Michael ; Suddath, Robert ; McCracken, James T. ; Spirito, Anthony ; Onorato, Matthew ; Zelazny, Jamie ; Porta, Giovanna ; Iyengar, Satish ; Brent, David A. / Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment : A follow-up study of the TORDIA sample. In: Journal of Clinical Psychiatry. 2011 ; Vol. 72, No. 3. pp. 388-396.
@article{650d86be04c6497c8c04d752581d427e,
title = "Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: A follow-up study of the TORDIA sample",
abstract = "Background: We examined the long-term outcome of participants in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study, a randomized trial of 334 adolescents (aged 12-18 years) with DSM-IV-defined major depressive disorder initially resistant to selective serotonin reuptake inhibitor (SSRI) treatment who were subsequently treated for 12 weeks with another SSRI, venlafaxine, another SSRI + cognitive-behavioral therapy (CBT), or venlafaxine + CBT. Responders then continued with the same treatment through week 24, while nonresponders were given open treatment. Method: For the current study, patients were reassessed 48 (n = 116) and 72 (n = 130) weeks from intake. Data were gathered from February 2001 to February 2007. Standardized diagnostic interviews and measures of depression, suicidal ideation, related psychopathology, and level of functioning were periodically administered. Remission was defined as ≥ 3 weeks with ≤ 1 clinically significant symptom and no associated functional impairment (score of 1 on the adolescent version of the Longitudinal Interval Follow-Up Evaluation [A-LIFE]), and relapse, as ≥ 2 weeks with probable or definite depressive disorder (score of 3 or 4 on the A-LIFE). Mixed-effects regression models were applied to estimate remission, relapse, and functional recovery. Results: By 72 weeks, an estimated 61.1{\%} of the randomized youths had reached remission. Randomly assigned treatment (first 12 weeks) did not influence remission rate or time to remission, but the group assigned to SSRIs had a more rapid decline in self-reported depressive symptoms and suicidal ideation than those assigned to venlafaxine (P < .03). Participants with more severe depression, greater dysfunction, and alcohol or drug use at baseline were less likely to remit. The depressive symptom trajectory of the remitters diverged from that of nonremitters by the first 6 weeks of treatment (P < .001). Of the 130 participants in remission at week 24, 25.4{\%} relapsed in the subsequent year. Conclusions: While most adolescents achieved remission, more than one-third did not, and one-fourth of remitted patients experienced a relapse. More effective interventions are needed for patients who do not show robust improvement early in treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00018902.",
author = "Benedetto Vitiello and Graham Emslie and Gregory Clarke and Karen Wagner and Asarnow, {Joan R.} and Keller, {Martin B.} and Boris Birmaher and Ryan, {Neal D.} and Betsy Kennard and Mayes, {Taryn L.} and Lynn DeBar and Frances Lynch and John Dickerson and Michael Strober and Robert Suddath and McCracken, {James T.} and Anthony Spirito and Matthew Onorato and Jamie Zelazny and Giovanna Porta and Satish Iyengar and Brent, {David A.}",
year = "2011",
month = "3",
doi = "10.4088/JCP.09m05885blu",
language = "English (US)",
volume = "72",
pages = "388--396",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment

T2 - A follow-up study of the TORDIA sample

AU - Vitiello, Benedetto

AU - Emslie, Graham

AU - Clarke, Gregory

AU - Wagner, Karen

AU - Asarnow, Joan R.

AU - Keller, Martin B.

AU - Birmaher, Boris

AU - Ryan, Neal D.

AU - Kennard, Betsy

AU - Mayes, Taryn L.

AU - DeBar, Lynn

AU - Lynch, Frances

AU - Dickerson, John

AU - Strober, Michael

AU - Suddath, Robert

AU - McCracken, James T.

AU - Spirito, Anthony

AU - Onorato, Matthew

AU - Zelazny, Jamie

AU - Porta, Giovanna

AU - Iyengar, Satish

AU - Brent, David A.

PY - 2011/3

Y1 - 2011/3

N2 - Background: We examined the long-term outcome of participants in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study, a randomized trial of 334 adolescents (aged 12-18 years) with DSM-IV-defined major depressive disorder initially resistant to selective serotonin reuptake inhibitor (SSRI) treatment who were subsequently treated for 12 weeks with another SSRI, venlafaxine, another SSRI + cognitive-behavioral therapy (CBT), or venlafaxine + CBT. Responders then continued with the same treatment through week 24, while nonresponders were given open treatment. Method: For the current study, patients were reassessed 48 (n = 116) and 72 (n = 130) weeks from intake. Data were gathered from February 2001 to February 2007. Standardized diagnostic interviews and measures of depression, suicidal ideation, related psychopathology, and level of functioning were periodically administered. Remission was defined as ≥ 3 weeks with ≤ 1 clinically significant symptom and no associated functional impairment (score of 1 on the adolescent version of the Longitudinal Interval Follow-Up Evaluation [A-LIFE]), and relapse, as ≥ 2 weeks with probable or definite depressive disorder (score of 3 or 4 on the A-LIFE). Mixed-effects regression models were applied to estimate remission, relapse, and functional recovery. Results: By 72 weeks, an estimated 61.1% of the randomized youths had reached remission. Randomly assigned treatment (first 12 weeks) did not influence remission rate or time to remission, but the group assigned to SSRIs had a more rapid decline in self-reported depressive symptoms and suicidal ideation than those assigned to venlafaxine (P < .03). Participants with more severe depression, greater dysfunction, and alcohol or drug use at baseline were less likely to remit. The depressive symptom trajectory of the remitters diverged from that of nonremitters by the first 6 weeks of treatment (P < .001). Of the 130 participants in remission at week 24, 25.4% relapsed in the subsequent year. Conclusions: While most adolescents achieved remission, more than one-third did not, and one-fourth of remitted patients experienced a relapse. More effective interventions are needed for patients who do not show robust improvement early in treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00018902.

AB - Background: We examined the long-term outcome of participants in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study, a randomized trial of 334 adolescents (aged 12-18 years) with DSM-IV-defined major depressive disorder initially resistant to selective serotonin reuptake inhibitor (SSRI) treatment who were subsequently treated for 12 weeks with another SSRI, venlafaxine, another SSRI + cognitive-behavioral therapy (CBT), or venlafaxine + CBT. Responders then continued with the same treatment through week 24, while nonresponders were given open treatment. Method: For the current study, patients were reassessed 48 (n = 116) and 72 (n = 130) weeks from intake. Data were gathered from February 2001 to February 2007. Standardized diagnostic interviews and measures of depression, suicidal ideation, related psychopathology, and level of functioning were periodically administered. Remission was defined as ≥ 3 weeks with ≤ 1 clinically significant symptom and no associated functional impairment (score of 1 on the adolescent version of the Longitudinal Interval Follow-Up Evaluation [A-LIFE]), and relapse, as ≥ 2 weeks with probable or definite depressive disorder (score of 3 or 4 on the A-LIFE). Mixed-effects regression models were applied to estimate remission, relapse, and functional recovery. Results: By 72 weeks, an estimated 61.1% of the randomized youths had reached remission. Randomly assigned treatment (first 12 weeks) did not influence remission rate or time to remission, but the group assigned to SSRIs had a more rapid decline in self-reported depressive symptoms and suicidal ideation than those assigned to venlafaxine (P < .03). Participants with more severe depression, greater dysfunction, and alcohol or drug use at baseline were less likely to remit. The depressive symptom trajectory of the remitters diverged from that of nonremitters by the first 6 weeks of treatment (P < .001). Of the 130 participants in remission at week 24, 25.4% relapsed in the subsequent year. Conclusions: While most adolescents achieved remission, more than one-third did not, and one-fourth of remitted patients experienced a relapse. More effective interventions are needed for patients who do not show robust improvement early in treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00018902.

UR - http://www.scopus.com/inward/record.url?scp=79953037056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953037056&partnerID=8YFLogxK

U2 - 10.4088/JCP.09m05885blu

DO - 10.4088/JCP.09m05885blu

M3 - Article

VL - 72

SP - 388

EP - 396

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 3

ER -